TeraRecon announced positive ratings in the recently released KLAS 2013 Advanced Visualization performance report entitled “Advanced Visualization 2013: How Advanced Is It?” TeraRecon’s general performance ratings were particularly noteworthy, in that the company received the top scores for the following general indicators:

Todd Dunlap, 62, arrived at Ronald Reagan UCLA Medical Center's emergency room on Aug. 8 suffering from shortness of breath, fatigue and extreme cold. When a computed (CT) scan revealed a 24-inch clot stretching from his legs into his heart, doctors feared the mass could break loose and lodge in his lungs, blocking oxygen and killing him instantly.

The Mount Sinai Medical Center is participating in the nationwide Absorb III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages. The randomized trial aims to compare the efficiency and safety of Absorb Bioresorbable Vascular Scaffolds (Absorb BVS) in coronary artery disease patients and compare it to the current standard of care — drug eluting metal stents.

Corindus Vascular Robotics announced the PRECISION Registry, an ongoing study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices. Giora Weisz, associate professor of Medicine at Columbia University Medical Center, will lead the study.

CardiacAssist launched the Protek17 Arterial Cannula, a key component of the TandemHeart temporary circulatory support platform used to rest the heart and circulate blood for patients with severe cardiac dysfunction. Protek17 is designed for improved patient safety and ease of use, with new features including suture wings for secure attachment to the patient and a rubber stop to prevent over-insertion, a common cause of vascular access site bleeding.

Boston Scientific reported favorable six-month results from the first 60 patients enrolled in the REPRISE II clinical trial evaluating the safety and performance of the Lotus Valve System in symptomatic patients with severe aortic stenosis considered at high risk for surgical valve replacement.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now